GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunocore Holdings PLC (STU:6YG) » Definitions » Purchase Of Investment

Immunocore Holdings (STU:6YG) Purchase Of Investment : €0.0 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Immunocore Holdings Purchase Of Investment?

Immunocore Holdings's purchase of investment for the three months ended in Dec. 2024 was €0.0 Mil. It means Immunocore Holdings spent €0.0 Mil on purchasing investments. Immunocore Holdings's purchase of investment for the trailing twelve months (TTM) ended in Dec. 2024 was €0.0 Mil.

Compared with last quarter (€0.0 Mil in Sep. 2024 ), Immunocore Holdings spent the same money on purchasing investments in Dec. 2024 (€0.0 Mil).

Immunocore Holdings Purchase Of Investment Historical Data

The historical data trend for Immunocore Holdings's Purchase Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunocore Holdings Purchase Of Investment Chart

Immunocore Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Purchase Of Investment
Get a 7-Day Free Trial - - - - -334.25

Immunocore Holdings Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Purchase Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Immunocore Holdings Purchase Of Investment Calculation

Purchase of Investments represents cash outflow on the purchase of investments in securities.

Purchase Of Investment for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunocore Holdings Purchase Of Investment Related Terms

Thank you for viewing the detailed overview of Immunocore Holdings's Purchase Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunocore Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunocore Holdings PLC (STU:6YG) » Definitions » Purchase Of Investment
Comparable Companies
IDYA MNKD WVE CLDX DYN LQDA VERA JANX AGIO SPRY VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
IMCR:USA
Address
92 Park Drive, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY
Website
https://www.immunocore.com
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Immunocore Holdings Headlines

No Headlines